Cambridge Investment Research Advisors
OCUL icon

Cambridge Investment Research Advisors’s Ocular Therapeutix OCUL Stock Holding History

Cambridge Investment Research Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$587K Buy
59,774
+2,700
+5% +$24.5K ﹤0.01% 2812
2026
Q1 		$483K Buy
57,074
+18,615
+48% +$177K ﹤0.01% 2837
2025
Q4 		$467K Buy
38,459
+9,359
+32% +$114K ﹤0.01% 2788
2025
Q3 		$340K Buy
29,100
+5,000
+21% +$59.8K ﹤0.01% 3006
2025
Q2 		$224K Buy
+24,100
New +$189K ﹤0.01% 3245

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Logos Global Management
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Cambridge Investment Research Advisors's OCUL Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its Ocular Therapeutix (OCUL) stake by 4.7% in Q2 2026, buying an estimated $24.5K and bringing the position to 59,774 shares worth $587K. The position accounts for ﹤0.01% of the portfolio, ranked #2812.

Cambridge Investment Research Advisors first reported a position in OCUL in Q2 2025 and has held it in 5 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Cambridge Investment Research Advisors held 59,774 shares of Ocular Therapeutix worth $587K as of Q2 2026.
  • Cambridge Investment Research Advisors bought 2,700 Ocular Therapeutix shares in Q2 2026, an estimated $24.5K.
  • Ocular Therapeutix made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #2812 holding.
  • Cambridge Investment Research Advisors first reported a position in Ocular Therapeutix in Q2 2025 and has held it in 5 quarters since.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.